Piramal Pharma Limited Announces Results for Q2 and H1 FY27

What happened

Piramal Pharma Limited reported consolidated revenue from operations of ₹2,617 crore for Q2 FY27, up 28% year on year, and ₹4,887 crore for H1 FY27, up 23%. EBITDA rose 72% in both periods and PAT turned positive at ₹5 crore in Q2.

Confirmed

Global impact / market context

Faster revenue growth across all three businesses, combined with higher factory usage and cost savings, lifted profit per sale, which means more of each rupee of sales becomes profit. That helps the company fund research, repay borrowed money and invest in capital spending without as much outside funding.

Analyst inference

The results show broad demand across contract development and manufacturing, which means making medicines for other companies, plus the consumer health and hospital generics businesses. Adding 22 new customers and completing 12 regulatory inspections suggests a fuller order pipeline, which can support revenue and factory usage in coming quarters.

Analyst inference

What to watch

1. Piramal added 22 new customers and hosted 110 customer audits in H1 FY27, while completing 12 regulatory inspections with no Official Action Indicated, a formal regulator flag of serious quality failures. Confirmed
2. Watch whether the company converts its recent order enquiries and new customer wins into signed contracts, since booked orders rather than discussions would support the next quarters of revenue. Proposed
3. Track whether EBITDA margin holds near 14.7%, because profit per sale depends on continued high factory usage and cost savings; any slip there would reduce cash available for capital spending. Analyst inference

Evidence

• Original source link unavailable